Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblast cells and materials [1][3] - The company holds over 240 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [3] - Hamid Khoja, Ph.D., the Chief Scientific Officer, will present at The Cell & Gene Meeting On The Mediterranean in Rome, highlighting a fibroblast cell-based therapeutic approach targeting chronic inflammation-mediated diseases [1][2] Company Overview - FibroBiologics is based in Houston and represents a new generation of medical advancements in cell therapy and tissue regeneration [3] - The company is actively engaged in the development of a pipeline of treatments aimed at chronic diseases, leveraging its extensive patent portfolio [3] Conference Details - The presentation titled "Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases" will take place on April 16, 2025, at 9:00 AM CEST [2] - The event is a significant gathering for the Advanced Therapy Medicinal Products community from Europe and beyond [1][2]
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean